CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director Leonard E. Post sold 1,000 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $30.76, for a total transaction of $30,760.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
CG Oncology Trading Down 3.7 %
CG Oncology stock opened at $26.94 on Wednesday. The firm has a 50 day simple moving average of $23.60 and a 200 day simple moving average of $29.15. CG Oncology, Inc. has a 1-year low of $14.80 and a 1-year high of $46.99. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of -18.97 and a beta of 1.24.
CG Oncology (NASDAQ:CGON - Get Free Report) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.11). CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.11 million. On average, equities research analysts forecast that CG Oncology, Inc. will post -1.31 EPS for the current year.
Hedge Funds Weigh In On CG Oncology
A number of large investors have recently modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in CG Oncology by 59.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 31,071 shares of the company's stock worth $1,172,000 after acquiring an additional 11,542 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of CG Oncology during the 4th quarter valued at $411,000. Vanguard Group Inc. raised its position in shares of CG Oncology by 15.3% in the fourth quarter. Vanguard Group Inc. now owns 5,861,082 shares of the company's stock worth $168,096,000 after buying an additional 779,730 shares in the last quarter. Barclays PLC boosted its stake in CG Oncology by 331.1% during the third quarter. Barclays PLC now owns 90,520 shares of the company's stock valued at $3,416,000 after buying an additional 69,523 shares during the period. Finally, Franklin Resources Inc. grew its position in CG Oncology by 8.9% during the third quarter. Franklin Resources Inc. now owns 1,230,193 shares of the company's stock worth $46,157,000 after buying an additional 100,106 shares in the last quarter. 26.56% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
CGON has been the topic of a number of research analyst reports. Scotiabank initiated coverage on CG Oncology in a research note on Wednesday, April 16th. They issued a "sector perform" rating and a $23.00 target price on the stock. Royal Bank of Canada boosted their price objective on CG Oncology from $66.00 to $68.00 and gave the stock an "outperform" rating in a research report on Tuesday. HC Wainwright restated a "buy" rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Monday. Morgan Stanley reiterated an "overweight" rating and set a $55.00 target price on shares of CG Oncology in a research note on Friday, March 7th. Finally, TD Cowen assumed coverage on shares of CG Oncology in a research report on Tuesday, January 7th. They set a "buy" rating for the company. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $59.56.
Get Our Latest Stock Analysis on CG Oncology
About CG Oncology
(
Get Free Report)
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.